Inhalant Allergen Screening Testing: Principles, Panels, Methods, and Clinical Applications

Inhalant allergen screening testing is a laboratory-based diagnostic approach that detects allergen-specific IgE antibodies against common airborne allergens such as house dust mites, pollens, animal dander, mold spores, and insect-derived allergens. By combining multi-allergen screening panels with component-resolved analysis, clinicians can accurately identify sensitization patterns underlying allergic rhinitis, asthma, and other IgE-mediated respiratory diseases. This article provides a comprehensive technical overview of sample types, testing items, analytical methods, clinical applications, and frequently asked questions related to inhalant allergen screening.

Technical Overview

Inhalant allergen screening testing refers to a category of in vitro and in vivo diagnostic procedures designed to detect sensitization to aeroallergens—airborne substances capable of triggering immunoglobulin E (IgE)-mediated type I hypersensitivity reactions. Common aeroallergen groups include house dust mites, tree/grass/weed pollens, animal epithelia and dander, fungal spores, and cockroach-derived allergens. The testing principle is based on the Gell and Coombs classification of type I hypersensitivity, in which repeated exposure to an inhalant allergen induces production of allergen-specific IgE (sIgE) that binds to high-affinity receptors on mast cells and basophils, leading to symptom release upon re-exposure.

A typical screening strategy employs a pooled inhalant allergen panel as an initial first-line assay. A positive screen indicates sensitization to one or more common aeroallergens and prompts reflex testing with individual allergen extracts or molecular components to identify the specific offending agent. Quantitative results are reported in kilounits of allergen-specific IgE per liter (kUA/L), with calibration traceable to the World Health Organization (WHO) International Reference Preparation for IgE. Allergen nomenclature follows the systematic conventions established by the International Union of Immunological Societies (IUIS), such as Der p 1 (Dermatophagoides pteronyssinus group 1) or Fel d 1 (cat major allergen).

It is important to distinguish sensitization (detectable sIgE) from clinical allergy (symptoms upon exposure). Screening results must therefore always be interpreted alongside the patient history and clinical presentation. Testing is typically performed in medical laboratories accredited to ISO 15189, following recognized clinical laboratory standards and external quality assessment schemes to ensure analytical accuracy and reproducibility.

Testing Samples

Serum or Plasma

Venous blood (typically 2–5 mL) is collected into a serum separator or plain tube, centrifuged, and the separated serum or plasma is used for allergen-specific IgE immunoassays. No fasting is required, and antihistamines, corticosteroids, and other medications generally do not interfere with in vitro IgE measurement, making serum-based testing suitable for patients who cannot discontinue medication. Specific IgE antibodies in serum remain stable under standard refrigerated storage and transport conditions.

Whole Blood

Capillary or venous whole blood may be used for rapid point-of-care or automated immunoassay platforms. This approach reduces sample volume requirements and is particularly useful for pediatric patients, outreach screening programs, and settings where immediate centrifugation is unavailable.

Environmental Dust Samples

For exposure assessment rather than patient sensitization testing, settled dust can be collected from mattresses, upholstered furniture, carpets, or air filtration units. Allergen burden (for example, Der p 1, Der f 1, Fel d 1, Can f 1) is quantified by enzyme-linked immunosorbent assay (ELISA) using allergen-specific monoclonal antibodies, providing objective data for environmental hygiene interventions.

Skin Test Sites (In Vivo Testing)

Skin prick testing does not require a laboratory specimen; instead, the volar forearm or back serves as the test site. Antihistamine medications must be withheld for the recommended washout period before testing to avoid false-negative reactions.

Testing Items

Testing items are generally organized into screening panels and individual allergens. A screening panel combines representative aeroallergens relevant to the regional environment into a single analytical reaction, while individual allergen testing confirms and specifies the sensitization profile.

Common Screening Panels

• Combined inhalant allergen screen (broad first-line panel of regionally prevalent aeroallergens)
• House dust mite mixture (Dermatophagoides pteronyssinus and D. farinae)
• Tree pollen mixture (birch, oak, cedar/cypress, plane, willow, poplar, elm)
• Grass pollen mixture (timothy, Bermuda, meadow fescue, ryegrass)
• Weed pollen mixture (ragweed, mugwort, plantain, goosefoot)
• Mold mixture (Alternaria, Cladosporium, Aspergillus, Penicillium)
• Epithelial and animal dander mixture (cat, dog, horse, rabbit, hamster, guinea pig)
• Cockroach mixture (German and American cockroach)

Individual Allergens and Molecular Components

• House dust mites: Dermatophagoides pteronyssinus, Dermatophagoides farinae, Blomia tropicalis
• Tree pollens: birch (Bet v), oak, cedar, cypress, plane tree
• Grass pollens: timothy (Phl p), Bermuda grass, ryegrass
• Weed pollens: ragweed (Amb a), mugwort (Art v), plantain
• Animal allergens: cat dander (Fel d), dog dander (Can f), horse epithelium
• Fungal allergens: Alternaria alternata (Alt a), Cladosporium herbarum (Cla h), Aspergillus fumigatus (Asp f)
• Insect allergens: German cockroach (Bla g), American cockroach (Per a)

Component-resolved testing further identifies sensitization to defined molecular allergens, such as Der p 1, Der p 2, Der p 10 (pan-allergenic tropomyosin), Bet v 1 (PR-10 protein), Phl p 1/Phl p 5, Amb a 1, Fel d 1, Alt a 1, and Bla g 2. Molecular components help distinguish genuine species-specific sensitization from cross-reactivity and support selection of patients for allergen immunotherapy.

Testing Methods

Skin Prick Testing (SPT)

Skin prick testing is an in vivo method in which a drop of standardized allergen extract is applied to the skin and introduced with a sterile lancet through the drop. Histamine serves as the positive control and saline as the negative control. A wheal diameter of 3 mm or greater than the negative control after 15–20 minutes indicates a positive reaction. SPT offers high sensitivity, immediate results, and low cost, but results can be affected by antihistamine use, dermatographism, and skin condition, and it requires performance by trained personnel with emergency preparedness.

Serum Allergen-Specific IgE Immunoassays

In vitro sIgE testing is performed on serum using automated or semi-automated immunoassay platforms, including fluorescent enzyme immunoassay (FEIA), chemiluminescent immunoassay (CLIA), and ELISA formats. Patient sIgE binds to solid-phase immobilized allergen (extract or recombinant component), and bound antibody is detected through enzyme- or chemiluminescence-labeled anti-IgE reagents. Results are quantified in kUA/L with calibration traceable to the WHO IgE reference standard and are commonly reported using a seven-grade classification:

• Class 0: below 0.35 kUA/L — no detectable specific IgE
• Class 1: 0.35–0.69 kUA/L — low level
• Class 2: 0.70–3.49 kUA/L — moderate level
• Class 3: 3.50–17.4 kUA/L — high level
• Class 4: 17.5–49.9 kUA/L — very high level
• Class 5: 50.0–99.9 kUA/L — very high level
• Class 6: 100 kUA/L or above — extremely high level

Higher classes correlate with an increased likelihood of clinical reactivity but do not linearly predict symptom severity.

Component-Resolved Diagnostics (CRD)

CRD utilizes purified native or recombinant allergen molecules instead of whole extracts, enabling precise differentiation between primary species-specific sensitization and cross-reactivity (for example, PR-10 cross-reactivity between birch and related fruits, or tropomyosin-mediated cross-reactivity among mites, shellfish, and cockroach). CRD improves the specificity of diagnosis and informs eligibility for targeted allergen immunotherapy.

Multiplex Molecular Allergy Assays

Microarray-based multiplex platforms allow simultaneous measurement of specific IgE to more than one hundred molecular allergens using a small serum volume. These assays are valuable for evaluating polysensitized patients, complex or unusual reaction patterns, and pediatric cases where sample volume is limited.

Supplementary Assays

• Total serum IgE: supportive marker influenced by atopy, parasitic infection, and other conditions; not diagnostic alone
• Basophil activation test (BAT): flow-cytometric functional assay measuring CD63/CD203c expression, used as a confirmatory tool in specialized settings
• Allergen challenge tests: performed only in controlled clinical environments for definitive confirmation

All analytical methods should be validated and operated under a quality management framework consistent with ISO 15189, with regular participation in external quality assessment programs and adherence to applicable clinical laboratory standards.

Applications

Inhalant allergen screening testing supports a wide range of clinical and occupational decision-making scenarios:

• Differentiating allergic rhinitis from non-allergic (vasomotor or infectious) rhinitis
• Phenotyping asthma and identifying aeroallergen triggers in patients with frequent exacerbations
• Selecting and monitoring candidates for allergen immunotherapy (subcutaneous or sublingual routes)
• Evaluating children with early-onset eczema, rhinitis, or wheeze to identify the atopic march and guide preventive counseling
• Assessing occupational respiratory sensitization in laboratory animal handlers, bakers, farmers, and other exposed workers
• Confirming pet-related sensitization before household or workplace decisions on animal exposure
• Quantifying indoor allergen burden through environmental dust analysis to guide avoidance measures for mites, pet dander, and cockroach allergens
• Supporting pre-employment, occupational health surveillance, and general health assessment programs through accredited third-party laboratories

FAQ

Does a positive screening result mean I have an allergy?

Not necessarily. A positive result confirms sensitization, meaning specific IgE antibodies are present. Clinical allergy requires that sensitization be consistent with symptoms upon exposure. A positive screen should always be interpreted together with the medical history and, when needed, follow-up individual or component testing.

What is the difference between a screening panel and individual allergen testing?

A screening panel pools several common aeroallergens into one reaction and provides a yes/no indication of inhalant sensitization. If positive, individual allergen testing identifies exactly which extract or component is responsible, forming the basis for targeted management or immunotherapy.

Blood test or skin prick test—which is better?

Both are accepted first-line methods. Skin prick testing is fast and sensitive but requires antihistamine withdrawal and intact skin. Serum specific IgE testing is not affected by medications, carries no risk of systemic reaction, and is preferred for infants, patients with widespread skin disease, and those unable to stop antihistamines. The two methods are often complementary.

Do I need to stop taking medications before testing?

Medication withdrawal is generally not required for serum specific IgE testing. For skin prick testing, oral antihistamines typically must be discontinued for 3–7 days beforehand, and certain other drugs may also interfere; always follow the instructions of the testing clinician.

Can young children and pregnant women be tested?

Yes. Serum specific IgE testing is safe for all age groups, including infants and pregnant women, since it involves only a standard blood draw with no allergen exposure. Interpretation in very young children should account for age-dependent IgE reference behavior.

What does the IgE class or kUA/L value mean?

The kUA/L value quantifies the amount of allergen-specific IgE in the sample, and the class (0–6) groups these concentrations into interpretive bands. Higher values indicate greater likelihood of clinical relevance, but they do not directly measure symptom severity.

How long does it take to get results?

Serum screening results are typically available within one to three working days, while larger individual panels or multiplex molecular assays may require additional time. Skin prick test results are read within 15–20 minutes at the point of care.

Can sensitization change over time?

Yes. Sensitization may develop, persist, or wane, particularly in children. Repeat testing may be warranted when symptoms change, when environmental exposure changes, or when monitoring the immunological response during allergen immunotherapy.